{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:59:54Z","timestamp":1783025994977,"version":"3.54.6"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91859207"],"award-info":[{"award-number":["91859207"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771873"],"award-info":[{"award-number":["81771873"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81471689"],"award-info":[{"award-number":["81471689"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11307-021-01628-7","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T19:02:31Z","timestamp":1625598151000},"page":"827-835","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Biodistribution of 18F-AlF-NOTA-octreotide in Different Organs and Characterization of Uptake in Neuroendocrine Neoplasms"],"prefix":"10.1007","volume":"23","author":[{"given":"Jiale","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nengan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"issue":"10","key":"1628_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA oncology 3(10):1335\u20131342","journal-title":"JAMA oncology"},{"issue":"12","key":"1628_CR2","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.3390\/ijms20123049","volume":"20","author":"AK Stueven","year":"2019","unstructured":"Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H (2019) Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future. Int J Mol Sci 20(12):3049","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1628_CR3","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","volume":"44","author":"MF Bozkurt","year":"2017","unstructured":"Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, Ambrosini V, Kjaer A, Delgado-Bolton R, Kunikowska J, Oyen WJG, Chiti A, Giammarile F, Sundin A, Fanti S (2017) Guideline for PET\/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging 44(9):1588\u20131601","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1628_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2967\/jnumed.117.202275","volume":"59","author":"TA Hope","year":"2018","unstructured":"Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR (2018) Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 59(1):66\u201374","journal-title":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine"},{"issue":"11","key":"1628_CR5","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s00259-019-04474-6","volume":"46","author":"K Goffin","year":"2019","unstructured":"Goffin K (2019) Al18F-NOTA-octreotide and 18F-SiFAlin-TATE: two \u2018new kids on the block\u2019 in somatostatin receptor imaging. Eur J Nucl Med Mol Imaging 46(11):2225\u20132227","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"1628_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.nucmedbio.2010.04.185","volume":"37","author":"HH Coenen","year":"2010","unstructured":"Coenen HH, Elsinga PH, Iwata R, Kilbourn MR, Pillai MRA, Rajan MGR, Wagner HN Jr, Zaknun JJ (2010) Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences. Nucl Med Biol 37(7):727\u2013740","journal-title":"Nucl Med Biol"},{"issue":"2","key":"1628_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/EJE-18-0321","volume":"179","author":"AMA Berends","year":"2018","unstructured":"Berends AMA, Kerstens MN, Bolt JW, Links TP, Korpershoek E, de Krijger RR, Walenkamp AME, Noordzij W, van Etten B, Kats-Ugurlu G, Brouwers AH, van der Horst-Schrivers A (2018) False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET ((18)F-FDOPA-PET) performed for imaging of neuroendocrine tumors. Eur J Endocrinol 179(2):125\u2013133","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1628_CR8","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2967\/jnumed.116.174714","volume":"57","author":"CB Johnbeck","year":"2016","unstructured":"Johnbeck CB, Knigge U, Langer SW, Loft A, Berthelsen AK, Federspiel B, Binderup T, Kjaer A (2016) Prognostic value of 18F-FLT PET in patients with neuroendocrine neoplasms: a prospective head-to-head comparison with 18F-FDG PET and Ki-67 in 100 patients. J Nucl Med 57(12):1851\u20131857","journal-title":"J Nucl Med"},{"issue":"19","key":"1628_CR9","first-page":"30235","volume":"S0003-4266","author":"M Jullien","year":"2019","unstructured":"Jullien M, Reichert T, D\u2019Anella P et al (2019) Comparison of 68Ga-Dotatate PET\/CT and 18F-FDOPA PET\/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient. Ann Endocrinol (Paris) S0003-4266(19):30235\u201330235","journal-title":"Ann Endocrinol (Paris)"},{"issue":"6","key":"1628_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/RLU.0000000000002578","volume":"44","author":"T Long","year":"2019","unstructured":"Long T, Yang N, Zhou M, Chen D, Li Y, Li J, Tang Y, Liu Z, Li Z, Hu S (2019) Clinical application of 18F-AlF-NOTA-octreotide PET\/CT in combination with 18F-FDG PET\/CT for imaging neuroendocrine neoplasms. Clin Nucl Med 44(6):452\u2013458","journal-title":"Clin Nucl Med"},{"issue":"3","key":"1628_CR11","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2967\/jnumed.109.066902","volume":"51","author":"P Laverman","year":"2010","unstructured":"Laverman P, McBride WJ, Sharkey RM et al (2010) A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med 51(3):454\u2013461","journal-title":"J Nucl Med"},{"issue":"6","key":"1628_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s12149-013-0718-4","volume":"27","author":"S Kuyumcu","year":"2013","unstructured":"Kuyumcu S, \u00d6zkan ZG, Sanli Y, Yilmaz E, Mudun A, Adalet I, Unal S (2013) Physiological and tumoral uptake of 68Ga-DOTATATE: standardized uptake values and challenges in interpretation. Ann Nucl Med 27(6):538\u2013545","journal-title":"Ann Nucl Med"},{"issue":"6","key":"1628_CR13","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1097\/RLU.0000000000001100","volume":"41","author":"F Moradi","year":"2016","unstructured":"Moradi F, Jamali M, Barkhodari A, Schneider B, Chin F, Quon A, Mittra ES, Iagaru A (2016) Spectrum of 68Ga-DOTA TATE uptake in patients with neuroendocrine tumors. Clin Nucl Med 41(6):e281\u2013e2e7","journal-title":"Clin Nucl Med"},{"issue":"4","key":"1628_CR14","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s00259-019-04611-1","volume":"47","author":"D Yadav","year":"2019","unstructured":"Yadav D, Ballal S, Yadav MP, Tripathi M, Roesch F, Bal C (2019) Evaluation of [68Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: comparison with [68Ga]Ga-DOTA-NOC PET\/CT. Eur J Nucl Med Mol Imaging 47(4):860\u2013869","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"1628_CR15","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1007\/s00259-019-04425-1","volume":"46","author":"E Pauwels","year":"2019","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, van Cutsem E, Verslype C, van Laere K, Bormans G, Deroose CM (2019) Al(18)F-NOTA-octreotide: first comparison with (68)Ga-DOTATATE in a neuroendocrine tumour patient. Eur J Nucl Med Mol Imaging 46(11):2398\u20132399","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"1628_CR16","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00259-020-04918-4","volume":"47","author":"E Pauwels","year":"2020","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, van Cutsem E, Verslype C, van Laere K, Bormans G, Deroose CM (2020) [(18)F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [(68)Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging 47(13):3033\u20133046","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1628_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5603\/NMR.2017.0003","volume":"20","author":"V Cuccurullo","year":"2017","unstructured":"Cuccurullo V, Di Stasio GD, Mansi L (2017) Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs. Nucl Med Rev Cent East Eur 20(1):49\u201356","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"1628_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jcpa.2018.11.002","volume":"166","author":"G Foiani","year":"2019","unstructured":"Foiani G, Guelfi G, Chiaradia E, Mancini F, Trivelli C, Vitellozzi G, Lepri E, Mandara MT (2019) Somatostatin receptor 2 expression in canine meningioma. J Comp Pathol 166:59\u201368","journal-title":"J Comp Pathol"},{"issue":"11","key":"1628_CR19","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1007\/s00259-016-3395-4","volume":"43","author":"I Virgolini","year":"2016","unstructured":"Virgolini I, Gabriel M, Kroiss A, von Guggenberg E, Prommegger R, Warwitz B, Nilica B, Roig G, Rodrigues M, Uprimny C (2016) Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 43(11):2072\u20132083","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1628_CR20","first-page":"117955141988405","volume":"12","author":"R Wang","year":"2019","unstructured":"Wang R, Zheng-Pywell R, Chen HA et al (2019) Management of gastrointestinal neuroendocrine tumors. Clinical Medicine Insights: Endocrinology and Diabetes 12:1179551419884058","journal-title":"Clinical Medicine Insights: Endocrinology and Diabetes"},{"issue":"7","key":"1628_CR21","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1097\/MPA.0000000000001356","volume":"48","author":"H Chan","year":"2019","unstructured":"Chan H, Moseley C, Zhang L, Bergsland EK, Pampaloni MH, van Loon K, Hope TA (2019) Correlation of DOTATOC uptake and pathologic grade in neuroendocrine tumors. Pancreas 48(7):948\u2013952","journal-title":"Pancreas"},{"issue":"10","key":"1628_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/RLU.0000000000002694","volume":"44","author":"DY Lee","year":"2019","unstructured":"Lee DY, Kim Y-I (2019) Prognostic value of maximum standardized uptake value in 68Ga-somatostatin receptor positron emission tomography for neuroendocrine tumors: a systematic review and meta-analysis. Clin Nucl Med 44(10):777\u2013783","journal-title":"Clin Nucl Med"},{"issue":"11","key":"1628_CR23","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/cncr.23469","volume":"112","author":"I Kayani","year":"2008","unstructured":"Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ (2008) Functional imaging of neuroendocrine tumors with combined PET\/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 112(11):2447\u20132455","journal-title":"Cancer"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-021-01628-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-021-01628-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-021-01628-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T14:30:31Z","timestamp":1636468231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-021-01628-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1628"],"URL":"https:\/\/doi.org\/10.1007\/s11307-021-01628-7","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]},"assertion":[{"value":"15 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study, formal consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}